Search results for: Maria Lowe
Filter search results
Biosimilars’ Price Dynamic in Europe
30 June 2010
…For example, since growth hormone is given primary to children and effects are visible only over the longer term, tolerance of risk and reduced efficacy is lower. EPO and insulin, in…
Estimating US Savings from Biosimilars
13 July 2010
…to interchangeability, market share will grow more slowly even in the face of lower prices if the FDA judges a biosimilar not to be fully interchangeable. Omnitrope, a biosimilar human growth hormone…
Part 1: 2010 Lecture on US Health Reform
20 July 2010
…federal government will spend $930 billion over ten years. This includes $358 billion to (1) subsidize the purchase of insurance by Americans at the lower end of the income spectrum, but…
Value Based Pricing in the UK
7 September 2010
…could be achieved by ensuring that NICE’s assessments are ‘”rigged” to justify demanding a lower price than the drug is worth to the NHS’. Introducing such potential bias would substantially…
Access to Orphan Drugs in the EU
21 October 2010
…lower risk-benefit ratios for OMPs than for other new medicines. When a formal health technology assessment (HTA) process is required, however, evidence requirements are the same as for non-OMP drugs (except…
Australia’s Publicly Funded Vaccines Market
1 December 2010
…between curative pharmaceutical products and vaccines. PBAC’s approach also may affect pricing by encouraging companies to offer a lower price in order to increase the vaccine’s calculated cost effectiveness. In…
Measuring Value: OHE at ISPOR
4 January 2011
…lower priority to others. Modern methods of utility measurement Nancy Devlin of OHE and Paul Krabbe from the University Medical Centre, Groningen, The Netherlands, presented a workshop that discussed a…
Update: Value-Based Pricing in the UK
11 January 2011
…post, a review by Towse[1] indicated that most PAS have been financial – lowering effective NHS transaction prices below list prices. Ending PAS could create problems: companies usually are not…
Drugs and Vaccines for Developing Countries
1 June 2011
…by lowering prices, including differential pricing, compulsory licensing and donations. With respect to neglected diseases, they examine policies intended to stimulate development of new medicines by reducing company-born costs and…